Cubist Systematic Strategies LLC Acquires 119,399 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Cubist Systematic Strategies LLC raised its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 2,428.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 124,316 shares of the company's stock after acquiring an additional 119,399 shares during the period. Cubist Systematic Strategies LLC owned about 0.08% of MiMedx Group worth $1,196,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after purchasing an additional 215,995 shares in the last quarter. Fiduciary Alliance LLC bought a new stake in shares of MiMedx Group during the 4th quarter worth approximately $160,000. SG Americas Securities LLC raised its stake in shares of MiMedx Group by 79.9% during the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock worth $802,000 after purchasing an additional 37,031 shares in the last quarter. Savant Capital LLC bought a new stake in shares of MiMedx Group during the 4th quarter worth approximately $100,000. Finally, Van ECK Associates Corp bought a new stake in shares of MiMedx Group during the 4th quarter worth approximately $40,000. Institutional investors own 79.15% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MDXG. StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

Insider Buying and Selling

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the company's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the transaction, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at $3,473,004.42. This represents a 11.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Joseph H. Capper acquired 200,000 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was purchased at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the completion of the acquisition, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. 1.70% of the stock is owned by insiders.

MiMedx Group Stock Performance

Shares of MDXG stock traded down $0.04 during trading on Friday, reaching $7.05. 614,522 shares of the company's stock were exchanged, compared to its average volume of 693,020. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $1.04 billion, a PE ratio of 12.82 and a beta of 1.85. MiMedx Group, Inc. has a twelve month low of $5.47 and a twelve month high of $10.14. The firm's fifty day moving average price is $7.19 and its 200-day moving average price is $8.16.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting analysts' consensus estimates of $0.06. The business had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. As a group, sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.